MedTrace Logo

Ventilatory Effects of THRIVE During EBUS

NCT05505279 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-08-15

No results posted yet for this study

Summary

High flow nasal cannula (HFNC) is used in interventional procedures to prevent hypoxia during sedation. In patients with a patent airway, HFNC reduces dead space ventilation as well. It is unknown if dead space ventilation is also reduced by HFNC in an EndoBroncheal UltraSound procedure, in which the airway is partially blocked by the endoscope. Especially in patients with Chronic Obstructive Pulmonary Disease (COPD) the partial blocking of the airway may reduce ventilation. If HFNC is able to reduce dead space during an EBUS-procedure, it may facilitate CO2 clearance, which may lead to a reduction in work of breathing.

This study aims to investigate if HFNC reduces dead space ventilation in patients undergoing an EBUS-procedure and if this is flow-dependent.

A randomized, double-blinded, cross-over study is designed.

Conditions

  • Hypercapnia
  • Sedation Complication
  • High Flow Nasal Cannula

Interventions

DEVICE

THRIVE (High Flow Nasal Cannula)

2 different rates of nasal flow compared to each other and a baseline of level of nasal oxygen

Sponsors & Collaborators

  • Fisher and Paykel Healthcare

    collaborator INDUSTRY

  • Rijnstate Hospital

    lead OTHER

Principal Investigators

  • Jeffrey Miechels · Dept. of Anesthesiology and Critical Care, Rijnstate Hospital, Arnhem

  • Mark V Koning, MD, PhD · Dept. of Anesthesiology and Critical Care, Rijnstate Hospital, Arnhem

  • Niels Claessens, MD, PhD · Dept. of Pulmonology, Rijnstate Hospital, Arnhem

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-05
Primary Completion
2024-08-08
Completion
2024-08-08

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05505279 on ClinicalTrials.gov